Why Enanta Pharmaceuticals, Inc.’s (ENTA) Stock Is Down 5.21%
As of Wednesday, October 28, Enanta Pharmaceuticals, Inc.’s ENTA share price has dipped by 5.21%, which has investors questioning if this is right time to buy.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company’s product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Commentary & Analysis
Why Enanta Pharmaceuticals, Inc.’s (ENTA) Stock Is Down 5.03%
As of Friday, October 23, Enanta Pharmaceuticals, Inc.’s ENTA share price has dipped by 5.03%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Enanta Pharmaceuticals, Inc.’s (ENTA) Stock Is Up 5.30%
As of Wednesday, September 30, Enanta Pharmaceuticals, Inc.’s ENTA share price has surged by 5.30%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Enanta Pharmaceuticals, Inc.’s (ENTA) Stock Is Down 5.49%
As of Tuesday, September 15, Enanta Pharmaceuticals, Inc.’s ENTA share price has dipped by 5.49%, which has investors questioning if this is right time to buy.Michael Rose
Why Enanta Pharmaceuticals, Inc.’s (ENTA) Stock Is Up 5.60%
As of Tuesday, August 25, Enanta Pharmaceuticals, Inc.’s ENTA share price has surged by 5.60%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | ENTA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $320.4 | $219.9 | 33% |
|
| Shares Out (Mil) | 29.1 | 54.1 | 36% |
|
| Institutional Ownership | 94.4% | 92.9% | 65% |
|
| Float (Mil) | 22.5 | 41.4 | 31% |
|
| Beta | 0.93 | 0.95 | 56% |
|
| Avg Daily Volume (000s) | 294 | 522 | 50% |
|
| Price Change (52-week) |
0.7% | 44.7% | 51% |
|
| Growth | ENTA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (11.8%) | 13.2% | 5% |
|
| Net Income (5yr) | (17.7%) | (10.1%) | 22% |
|
| EPS (5yr) | (16.2%) | 15.8% | 17 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (16.5%) | (15.7%) | 43% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 4 | 5 | |
| Current EPS | ($0.770) | ($2.293) | ($2.374) | |
| Month Ago EPS | ($0.770) | ($2.293) | ($2.374) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.644) | ($1.910) | ($2.072) | |
| Year/Year Chg | 14.9% | (40.3%) | (40.8%) | |
| Financials | ENTA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $65 | $38 | 22% |
|
| Net Income (TTM) (Mil) | ($63) | ($44) | 14% |
|
| EPS (TTM) | ($2.336) | ($1.500) | 13% |
|
| Operating Cash Flow (TTM) (Mil) | ($35) | ($35) | 12% |
|
| Net Cash Flow (TTM) (Mil) | ($11) | $0 | 31% |
|
| Long-Term Debt (Q1) (Mil) | $141 | $4 | 47% |
|
| Enterprise Value (Q1) (Mil) | $362 | $166 | 31% |
|
| Valuation | ENTA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.17 | 2.06 | 70% |
|
| P/E | na | 16.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | ENTA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 67.3% | 96% |
|
| Net Margin | (96.9%) | (61.0%) | 8% |
|
| ROA | (21.2%) | (47.5%) | 20% |
|
| ROE | (70.1%) | (52.7%) | 12% |
|
| Liabilities to Assets | 66.0% | 29.6% | 62% |
|
| F-Score | 4 | 3 | 33% |
|
Enanta Pharmaceuticals, Inc. did not pass any screens on 11/6/2026.
